067 BELCOMID: Belgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases

October 2021 in “ Journal of Investigative Dermatology ”

Tom Hillary, An Van Laethem, Francisca Castelijns, Séverine Vermeire, Jeroen Geldof, Marc Ferrante, Kurt de Vlam, Patrick Verschueren, João Sabino, Triana Lobatón, Hilde Lapeere, Debabrata Bandyopadhyay

psoriasis hidradenitis suppurativa atopic dermatitis SARS-CoV2 IgG COVID-19 seroprevalence seroconversion Targeted Immune-Modulating Therapies conventional systemic treatment TIMT

TLDR COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.

The study "067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases" conducted at two Belgian university hospitals involved 2166 patients with Immune Mediated Inflammatory diseases (IMID) such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. The study, which took place between 17/12/2020 and 28/02/2021, aimed to investigate the seroprevalence of SARS-CoV2 IgG in relation to previous exposure to COVID-19 and ongoing IMID treatment. Of the 1913 patients who completed the survey, 372 (19.5%) reported symptoms suggestive of COVID-19, and 96 (5.04%) had a positive SARS-CoV2 PCR test. Among those who tested positive, 45.8% showed anti-SARS-CoV2 IgG seroconversion, with no significant difference in seroconversion rate between those on Targeted Immune-Modulating Therapies (TIMT) and conventional systemic treatment. The study concluded that the prevalence of COVID-19 symptoms and confirmed cases remained low in this IMID cohort, regardless of treatment modality.

View this study on jidonline.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research What Causes Hidradenitis Suppurativa?—15 Years After

78 citations, October 2020 in “Experimental Dermatology”

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

research Patients With Specific Skin Disorders Affected by COVID-19: What Do Experiences Say About Management Strategies? A Systematic Review

31 citations, June 2020 in “Dermatologic Therapy”

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

research Dermatological Manifestations Associated with COVID-19: A Comprehensive Review of the Current Knowledge

25 citations, July 2021 in “Journal of Medical Virology”

COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.

research Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review

101 citations, July 2020 in “Dermatologic therapy”

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Drug Interactions Between Common Dermatological Medications and the Oral Anti-Covid-19 Agents Nirmatrelvir-Ritonavir and Molnupiravir

research Drug Interactions Between Common Dermatological Medications and the Oral Anti-Covid-19 Agents Nirmatrelvir-Ritonavir and Molnupiravir

5 citations, December 2022 in “Annals Academy of Medicine Singapore”

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

067 BELCOMID: Belgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases

Related Community Posts Join

community LPT: If your scalp is greasy, itchy, you have flakes and other crud, get a Psoriasis shampoo

community Few questions about my futur treatment

community 1.5yrs Fin 5m Min.. wow it was bad

community 27M after 10 Months on Oral Fin